Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA3 | P07451 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30799504 | 1.00 | IMPDH2 (0.50) | IMPDH2NR4A2CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL8834789 | 0.98 | IMPDH2 (0.49) | IMPDH2NR4A2CA12CA1CA2 | |
| SCHEMBL28251367 | 0.80 | DYRK1A (0.60) | NR4A2CA12CA1CA2CA3 | |
| SCHEMBL12865280 | 0.75 | TRIM24 (0.55) | NR4A2CA12CA1CA2CA3 | |
| SCHEMBL30215956 | 0.75 | IMPDH2 (0.50) | IMPDH2NR4A2TSHRALDH1A1TDP1 | |
| SCHEMBL24743296 | 0.75 | DYRK1A (0.55) | NR4A2CA12CA1CA2CA3 | |
| SCHEMBL7089054 | 0.75 | REN (0.50) | IMPDH2NR4A2HTR2ATSHRALDH1A1 | |
| SCHEMBL28002632 | 0.75 | IMPDH2 (0.50) | IMPDH2HTR2ATSHRALDH1A1TDP1 | |
| SCHEMBL5266825 | 0.75 | IMPDH2 (0.50) | IMPDH2NR4A2TSHRALDH1A1TDP1 | |
| SCHEMBL13094226 | 0.72 | IMPDH2 (0.51) | IMPDH2HTR2ATSHRALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1221533-C | Heterobicyclic sulfonamide derivative and sulfonic ester derivative | EISAI CO LTD (JP) | 2005-10-05 | — | — | CN | claimed |
| US-20260116874-A1 | HETEROAROMATIC INDOLESULFONAMIDES | SEED THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4724106-A1 | PROTACS AND HYT-PD MOLECULES FOR TARGETED PROTEIN DEGRADATION OF DCAF15 AND THEIR USE IN THE TREATMENT OF AMYLOIDOSIS | Kræftens bekæmpelse (DK) | 2026-04-15 | — | — | EP | disclosed |
| EP-4704836-A1 | HETEROAROMATIC INDOLESULFONAMIDES | Seed Therapeutics, Inc (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250368627-A1 | PYRAZOLESULFONAMIDES AS ANTITUMOR AGENTS | Peloton Therapeutics, Inc., a fully owned subsidiary of Merck Sharp & Dohme LLC (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4634155-A1 | RBM39 SULFONAMIDE INHIBITORS | Recursion Pharmaceuticals, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| CN-119630658-A | Heterocyclic RBM39 modulators | 递归医药公司 | 2025-03-14 | — | — | CN | disclosed |
| WO-2024251876-A1 | PROTACs AND HyT-PD MOLECULES FOR TARGETED PROTEIN DEGRADATION OF DCAF15 AND THEIR USE IN THE TREATMENT OF AMYLOIDOSIS | KRæFTENS BEKæMPELSE (DK) | 2024-12-12 | — | — | WO | disclosed |
| CN-115666575-B | Compounds and uses thereof | 福宏治疗公司 | 2024-12-10 | — | — | CN | disclosed |
| US-20240390387-A1 | SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-11-28 | — | — | US | disclosed |
| US-6544981-B2 | Anticoagulants, cardiovascular disorders | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-08 | — | — | US | disclosed |
| EP-1294716-A1 | LACTAM INHIBITORS OF FACTOR XA AND METHOD | Bristol-Myers Squibb Company (US) | 2003-03-26 | — | — | EP | disclosed |
| CN-1396833-A | Integrin expression inhibitors | EISAI CO LTD (JP) | 2003-02-12 | — | — | CN | disclosed |
| EP-1258252-A1 | INTEGRIN EXPRESSION INHIBITORS | Eisai Co., Ltd. (JP) | 2002-11-20 | — | — | EP | disclosed |
| WO-2002034744-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-05-02 | — | — | WO | disclosed |
| US-20020025957-A1 | Lactam inhibitors of factor Xa and method | BRISTOL-MYERS SQUIBB COMPANY | 2002-02-28 | — | — | US | disclosed |
| CN-1079097-C | Heterobicyclic sulfonamide derivatives and sulfonate derivatives | EISAI CO LTD (JP) | 2002-02-13 | — | — | CN | disclosed |
| WO-2001096331-A1 | LACTAM INHIBITORS OF FACTOR XA AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| CN-1114506-A | Heterobicyclic sulfonamide derivatives and sulfonate derivatives | EISAI CO LTD (JP) | 1996-01-03 | — | — | CN | disclosed |
| EP-0673937-A1 | BICYCLIC HETEROCYCLIC SULFONAMIDE AND SULFONIC ESTER DERIVATIVES | Eisai Co., Ltd. (JP) | 1995-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116874-A1 | HETEROAROMATIC INDOLESULFONAMIDES | DCAF1, DCAF15, DDX39B | IMPDH2 2210/4885NR4A2 1356/4885CA12 3806/4885 |
| US-20250368627-A1 | PYRAZOLESULFONAMIDES AS ANTITUMOR AGENTS | RBM39, RBM3, RBM28 | IMPDH2 2527/4885NR4A2 2756/4885CA12 4554/4885 |
| US-20240390387-A1 | SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF | BRD4, BRD1, BRD2 | IMPDH2 3263/4885NR4A2 1278/4885CA12 4426/4885 |
| US-20020025957-A1 | Lactam inhibitors of factor Xa and method | F9, F7, F11 | IMPDH2 2809/4885NR4A2 3138/4885CA12 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.